Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. - Wikidata - awgldk - TriplyDB

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

http://www.wikidata.org/entity/Q46688826

about

Vedolizumab for induction and maintenance of remission in Crohn’s disease Anti-MAdCAM antibody for induction of remission in ulcerative colitis Vedolizumab for induction and maintenance of remission in ulcerative colitis Natalizumab for relapsing remitting multiple sclerosis Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis Vedolizumab for the treatment of ulcerative colitis and Crohn's disease The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Review of vedolizumab for the treatment of ulcerative colitis Integrin-based therapeutics: biological basis, clinical use and new drugs Hepatic manifestations of non-steroidal inflammatory bowel disease therapy Current stage in inflammatory bowel disease: What is next?Pharmacologic therapy for inflammatory bowel disease refractory to steroids Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys Shining a light on intestinal traffic Review article: anti-adhesion therapies for inflammatory bowel disease Inflammatory pathways of importance for management of inflammatory bowel disease How Natalizumab Binds and Antagonizes 4 Integrins Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis The Dual Role of Neutrophils in Inflammatory Bowel Diseases Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease Zinc and gastrointestinal disease The safety of vedolizumab for the treatment of ulcerative colitis.Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Biologics in inflammatory bowel disease: what are the data?Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes.A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease.Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis New Data on the Use of Biologic Agents for Crohn's Disease and Ulcerative Colitis: Highlights from the 2009 CCFA Advances in IBD Meeting Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression.Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting.The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory bowel disease.

P2860

Q24187571-3A5EB1BA-B982-4A2C-B2E6-BDFD3E0B790A Q24187593-CB0F6029-60D5-49A7-AF8F-364FB138FE76 Q24194423-E2119F77-9780-4683-8AE6-92F07C5C1C6C Q24235861-FCD56AD1-21BA-4ADF-AE4D-5F6FD7350EFC Q24241123-C0CC6419-FE55-48F3-9E72-1665FFC47092 Q24630083-C8E1245B-3315-4827-BB7E-90BA387A19EA Q26745725-96D83C42-47F3-4D0B-A4AD-3F9960B15BF5 Q26750456-C696B4EE-BDA1-443B-934D-67C41DA9F901 Q26768259-8EF34C21-551E-439B-AC30-49CAA7D5FC6F Q26773026-73427276-6B69-42C7-917F-2DD3E28B92B4 Q26773684-1E980D1C-298A-4591-BDB3-E2BEA17D4B23 Q26777429-98C54E92-431A-40E8-95D0-BB2FB8D799DD Q26796415-7DD0766C-69FC-4904-9E66-EF49019C7287 Q26822029-247AEFF3-1E3B-46D3-ABBC-7E0729A92735 Q26822941-9E142435-36BC-467F-8A77-8485BF605FCF Q26852514-A077F342-EC51-4923-BFFB-EF98CAE3AC05 Q26862821-26DAAA44-01FE-4BB6-8BE0-D748DA7420B2 Q26863227-A47AC233-A2A9-4AE7-9CA4-BBE5EFBFED76 Q26999705-E9831CAC-1F78-4E68-BD01-80B5E66F1799 Q27005445-58D28E81-E9E4-4835-B84D-209F9D74E790 Q27679979-7C581EB4-66BF-4F82-9F51-F5E8F4328246 Q28067760-C1C28946-128E-44F5-858D-5015F402823A Q28080144-A2448331-68EB-456E-B6DE-33FFAAA488F3 Q28080984-F36A2649-E477-4E1E-A24C-053138C29FC2 Q28083872-CA9C3485-236F-41BC-9E3D-198511051852 Q28084236-FF505392-E512-4D3E-8A26-845DA16CC37A Q28538974-DF506F87-AACF-486C-940B-D9C5FFE47177 Q28652224-82DA77F6-592A-4D34-BE3F-FDE4669BA5C9 Q30235363-4CC4FD74-486A-460C-B4E8-6EAA2204B379 Q30300234-5ECE5205-FA81-4C93-84D3-1EFE624B9C2A Q30902172-1A2014FD-6B73-489A-988F-7285A0C434FE Q31017419-AC1DAD09-C758-4729-A074-DB5B289DE5E6 Q33509456-921A1396-DC0C-4EA6-AB83-1980FA8433BF Q33514539-AE64128D-5068-4517-B6E2-38FBC94C350C Q33564492-10AF30E0-96E7-4C2B-B6DB-6E76AD00C9A1 Q33612263-FC2EB52C-6111-4570-9F26-7BB2C0C87123 Q33802845-B56186DC-D51D-47D8-82C3-8695E11F3190 Q33898626-5E7C14DA-18E6-4C27-9707-DB1124D06DC0 Q33916292-03AD0ECA-BA5D-41CF-B142-71BC7E8C9FBA Q33949950-950E3242-B58F-450D-BF9D-9D879043ED3A

P2860

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

http://www.wikidata.org/entity/Q46688826

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

@en

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

@nl

type

label

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

@en

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

@nl

prefLabel

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

@en

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

@nl

P1433

Q46688826-74E711D4-CE49-4116-8F2E-F04DD46C96E3

P1476

Q46688826-A2410876-0347-41C8-83C0-4542373874E6

P2093

Q46688826-05AE6FB6-C5FE-49CA-A98F-78CE06317FBB

Q46688826-18BFB06E-B6FB-46DD-A022-F2987EE32B7C

Q46688826-49C88959-80BE-4E18-B520-93D6428434C8

Q46688826-6D4B559F-223F-4100-A63F-8BECACD7F204

Q46688826-7D964A20-FFB1-4D43-893A-FA01DDF40347

Q46688826-8B247B5F-ED0E-437B-8134-889FFA6A1AD4

Q46688826-9541D788-B8D3-4B9C-9825-37CBBFC5C025

Q46688826-A055AF3F-5FB8-4F00-AFB6-8288FD7ABBF9

Q46688826-A319FFE4-34CE-4086-B58C-EDBA1A902048

Q46688826-D01AAD0D-BB14-42A4-840F-EC1191E29AB9

P304

Q46688826-CBBE8F39-3EB0-41B0-B0E9-A7756EC83E76

P31

Q46688826-A2349E4C-EA3A-4C58-8FF4-4734EBFF4F20

P356

Q46688826-2F6D29F4-F8AC-4490-8281-9A75EF0919F7

P407

Q46688826-0BBDDD43-FAB3-4379-8959-34F94EEE660C

P433

Q46688826-D8EDA154-86ED-4D10-9904-9235E155F0EA

P478

Q46688826-B20AAD4B-6143-4158-BE26-B9DAF6D3825E

P50

Q46688826-5A68B2C5-4E4C-4D77-85DA-BD35BAA636CC

Q46688826-6CF668D3-7A55-4543-B2D4-6A924F0055A8

Q46688826-FCD414BA-EFFC-4E50-8E3E-60F49C7D1F49

P577

Q46688826-E71C960A-A850-4ECF-B040-3755C6E59E62

P5875

Q46688826-D4C0073B-B21C-4AC1-8A17-B5AF66652CC8

P698

Q46688826-CD0A18CF-54AE-428A-8618-48451E612BF5

P356

J.GASTRO.2007.03.024

P1433

Gastroenterology

P1476

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

@en

P2093

Bret A Lashner

http://www.w3.org/2001/XMLSchema#string

Chito Hernandez

http://www.w3.org/2001/XMLSchema#string

Daniel H Present

http://www.w3.org/2001/XMLSchema#string

Douglas C Wolf

http://www.w3.org/2001/XMLSchema#string

International Efficacy of Nata ...... Remission (ENCORE) Trial Group

http://www.w3.org/2001/XMLSchema#string

Jeffrey Bornstein

http://www.w3.org/2001/XMLSchema#string

Martina E Spehlmann

http://www.w3.org/2001/XMLSchema#string

Miroslava Volfova

http://www.w3.org/2001/XMLSchema#string

Paul J Rutgeerts

http://www.w3.org/2001/XMLSchema#string

Remo Panaccione

http://www.w3.org/2001/XMLSchema#string

P304

1672-1683

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2007.03.024

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P50

Richard N. Fedorak

William Jeffery Sandborn

Brian G. Feagan

P577

2007-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6346277

http://www.w3.org/2001/XMLSchema#string

P698

17484865

http://www.w3.org/2001/XMLSchema#string